Outlook Therapeutics shares are trading lower after the company received Complete Response Letter (CRL) from the FDA for ONS-5010 BLA for the treatment of Wet AMD.
Portfolio Pulse from Benzinga Newsdesk
Outlook Therapeutics' shares are trading lower following the receipt of a Complete Response Letter (CRL) from the FDA for ONS-5010 BLA, a treatment for Wet AMD.
August 30, 2023 | 10:20 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Outlook Therapeutics' stock price is expected to decrease in the short term due to the FDA's Complete Response Letter for ONS-5010 BLA.
The FDA's Complete Response Letter is a setback for Outlook Therapeutics as it indicates that the FDA is not ready to approve the ONS-5010 BLA. This negative regulatory development is likely to impact investor sentiment and lead to a decrease in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100